- Home
- CGC vs IKT Comparison
CGC vs IKT Comparison
Compare CGC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGC
- IKT
- Stock Information
- Founded
- CGC 2009
- IKT 2008
- Country
- CGC Canada
- IKT United States
- Employees
- CGC N/A
- IKT N/A
- Industry
- CGC Pharmaceuticals and Biotechnology
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- CGC Health Care
- IKT Health Care
- Exchange
- CGC Nasdaq
- IKT Nasdaq
- Market Cap
- CGC 174.9M
- IKT 168.0M
- IPO Year
- CGC N/A
- IKT 2020
- Fundamental
- Price
- CGC $1.31
- IKT $2.00
- Analyst Decision
- CGC Sell
- IKT Buy
- Analyst Count
- CGC 2
- IKT 2
- Target Price
- CGC $2.00
- IKT $8.00
- AVG Volume (30 Days)
- CGC 7.7M
- IKT 113.6K
- Earning Date
- CGC 05-29-2025
- IKT 05-14-2025
- Dividend Yield
- CGC N/A
- IKT N/A
- EPS Growth
- CGC N/A
- IKT N/A
- EPS
- CGC N/A
- IKT N/A
- Revenue
- CGC $192,343,833.00
- IKT N/A
- Revenue This Year
- CGC N/A
- IKT N/A
- Revenue Next Year
- CGC $7.13
- IKT N/A
- P/E Ratio
- CGC N/A
- IKT N/A
- Revenue Growth
- CGC N/A
- IKT N/A
- 52 Week Low
- CGC $0.77
- IKT $1.12
- 52 Week High
- CGC $11.95
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- CGC 54.05
- IKT 46.57
- Support Level
- CGC $1.22
- IKT $1.78
- Resistance Level
- CGC $1.43
- IKT $2.13
- Average True Range (ATR)
- CGC 0.14
- IKT 0.16
- MACD
- CGC 0.00
- IKT -0.01
- Stochastic Oscillator
- CGC 41.38
- IKT 37.61
About CGC Canopy Growth Corporation
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.